Description: Cridanimod sodium, sodium salt of Cridanimod (XBIO-101; Virexxa), is a novel and potent immunomodulator and interferon inducer with antineoplastic activity. It acts as a progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod can increase progesterone receptor (PR) expression and is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy.
References: [1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa(R) in Endometrial Cancer. AUGUST 19, 2016
[2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
Related CAS #: 38609-97-1 (free acid) 58880-43-6 (sodium)
纯度：≥98%
CAS：58880-43-6
